Breast Cancer
Conditions
Keywords
autologous vaccination, GM-CSF, adenoviral mediated gene transfer, Stage IV breast cancer
Brief summary
The purpose of this trial is to test the safety of a vaccine made from a patient's own breast cancer cells, and determine if this vaccine will delay or stop the growth of the cancer. The vaccine is made by genetically modifying a patient's own tumor cells to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF) to activate the immune response
Detailed description
After the patient has given their consent to participate in the trial, a series of tests will be performed to determine if the patient is eligible. These tests may take place up to 21 days before the surgery to remove a tumor sample or cancer-containing fluid, which will be used to create the vaccines. The tumor cells or fluid is then brought to a special, certified laboratory where the vaccine is made. Specially trained laboratory technicians then use a method known as adenoviral mediated gene transfer, which adds a new gene to the cancer cells. This gene causes the cells to make GM-CSF, a powerful hormone that stimulates the immune system. The cells are then given radiation so that they will not grow. Participants will start receiving vaccine on day 1, 8, 15, 29, and then every two weeks until the supply of vaccine has run out. The amount of the vaccine depends upon the total amount of cells that are obtained from the breast cancer tumor or fluid. Each time the patient is vaccinated, they will be given injections that will be placed underneath the skin. A different place will be used for each injection. If there are enough cells from the patient's tumor sample, the patient will be given an injection of non-transduced irradiated cells (the gene was not added) . These cells will help to measure how the patient's immune system is reacting to the tumor cells. This is called Delayed-Type Hypersensitivity (DTH). With vaccine #1 and #5, the patient will also receive a DTH injection. Two to three days after the vaccine and DTH injection, skin biopsies will be taken of both sites. At week 10 in the study treatment, or earlier if necessary, the patient will have a chest, abdomen, and pelvic CT scan to determine if the vaccine therapy has had an effect on their disease. A brain MRI will be performed if there were any abnormalities on the first brain MRI or if new symptoms have developed. Patients may participate in this study until one of the following happens: All vaccine created from the tumor has been given to the patient; the patient's disease worsens; the patient experiences an unacceptable and/or harmful side effect; the patient is unable to follow the study plan; or the patient's doctor feels it is no longer in the best interest of the patient to continue.
Interventions
Vaccination with autologous tumor cells engineered by adenoviral mediated gene transfer to secrete GM-CS
Sponsors
Brigham and Women's Hospital
Dana-Farber Cancer Institute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically or cytologically confirmed invasive breast cancer, pre-operative stages II-III per AJCC 6th edition, based on baseline evaluation by clinical examination and/or breast imaging * Cohort 1: At least 2cm of residual disease in sum of diameters by clinical or radiographic findings following their preoperative chemotherapy * Cohort 2: Patients who have not received preoperative chemotherapy must have at least 4cm of disease in the largest diameter by clinical or radiographic findings * Prior therapy for Cohort 1 only: Must have completed preoperative (neoadjuvant) chemotherapy with either a standard regimen (containing an anthracycline and/or a taxane) or on a clinical trial * HER2 positive tumors must have received at least one prior trastuzumab-based therapy, and may not receive concurrent trastuzumab therapy and vaccination * Must initiate hormonal therapy (if indicated), including ovarian suppression, at least 4 weeks prior to initiation of vaccinations * Must have completed definitive resection of primary tumor with adequated excision of gross disease. Surgery should have occured more than 28 days but within 12 weeks prior to enrollment * May receive concurrent hormonal therapy, such as tamoxifen, ovarian suppression, and aromatase inhibitors * Must have had prior banked tumor of sufficient cellular yield for vaccination * ECOG Performance Status 0 or 1 * 18 years of age or older * Greater than 4 weeks from immunotherapy, or systemic glucocorticoid therapy * Adequate recovery from recent surgery and radiation therapy
Exclusion criteria
* Uncontrolled active infection or illness * Other medical or psychiatric illness or social situation that would limit study compliance * Pregnancy or nursing mothers * Evidence of HIV infection * Previous participation in an adenovirus-based trial * Concurrent invasive malignancies
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Minimum Number of Vaccine Doses Created Using Participant Tumor Sample | 40 Months | Tumor samples were obtained via malignant effusion or a surgically accessible tumor nodule of 2 cm in greatest diameter. Tumor cells were processed to single cell suspension and transduced with adenoviral vector encoding human Granulocyte-macrophage colony-stimulating factor (GM-CSF). Then, the cells washed extensively and irradiated with 10,000 cGy. Over the next 14 days, sterility cultures were tested for endotoxin and mycoplasma contamination. Individual vaccine cell dose and number varied depending on the final cell yield from vaccine production. For stage II-III patients, the minimal dose was 1 x 10\^5 cells and the maximal dose was 4 x 10\^6 cells. For metastatic patients, the minimal dose was 1 x 10\^5 cells and the maximal dose was 1 x 10\^7 cells. |
| Number of Participants With Grade 3 or Higher Adverse Events | Up to 58 Months | Number of participants with grade 3 or higher adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Median Follow-up Time by Survival Status | Up to 14 Years | Participants followed for survival status. Participants who were alive were noted as such as late as December 2020. |
Countries
United States
Participant flow
Recruitment details
January 2006 through May 2008
Participants by arm
| Arm | Count |
|---|---|
| Metastatic Breast Cancer Cohort Biological/Vaccine: Autologous, Lethally Irradiated Breast Cancer Cells Vaccine will be administered on days 1, 8, 15, 29 and then every 2 weeks until the supply of vaccine runs out
Autologous, Lethally Irradiated Breast Cancer Cells: Vaccination with autologous tumor cells engineered by adenoviral mediated gene transfer to secrete GM-CS | 7 |
| Total | 7 |
Baseline characteristics
| Characteristic | Metastatic Breast Cancer Cohort |
|---|---|
| Age, Continuous | 51.5 years |
| Clinical Stage T3, N1 | 3 Participants |
| Clinical Stage T4, N0, M1 | 1 Participants |
| Clinical Stage T4, N1 | 2 Participants |
| Clinical Stage T4, N2 | 1 Participants |
| Hormone Receptor Status Negative | 2 Participants |
| Hormone Receptor Status Positive | 5 Participants |
| Human Epidermal Growth Factor Receptor 2 Status Negative | 6 Participants |
| Human Epidermal Growth Factor Receptor 2 Status Positive | 1 Participants |
| Pathologic Response to Neoadjuvant Therapy Not Available | 1 Participants |
| Pathologic Response to Neoadjuvant Therapy Partial Response | 6 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 7 Participants |
| Sex: Female, Male Female | 7 Participants |
| Sex: Female, Male Male | 0 Participants |
| Triple Negative Negative | 5 Participants |
| Triple Negative Positive | 2 Participants |
| Type of Surgery Lumpectomy | 1 Participants |
| Type of Surgery Mastectomy | 6 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 5 / 7 |
| other Total, other adverse events | 7 / 7 |
| serious Total, serious adverse events | 1 / 7 |
Outcome results
Primary
Minimum Number of Vaccine Doses Created Using Participant Tumor Sample
Tumor samples were obtained via malignant effusion or a surgically accessible tumor nodule of 2 cm in greatest diameter. Tumor cells were processed to single cell suspension and transduced with adenoviral vector encoding human Granulocyte-macrophage colony-stimulating factor (GM-CSF). Then, the cells washed extensively and irradiated with 10,000 cGy. Over the next 14 days, sterility cultures were tested for endotoxin and mycoplasma contamination. Individual vaccine cell dose and number varied depending on the final cell yield from vaccine production. For stage II-III patients, the minimal dose was 1 x 10\^5 cells and the maximal dose was 4 x 10\^6 cells. For metastatic patients, the minimal dose was 1 x 10\^5 cells and the maximal dose was 1 x 10\^7 cells.
Time frame: 40 Months
Population: Vaccinations prepared for enrolled for vaccine administration population.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Vaccine | Minimum Number of Vaccine Doses Created Using Participant Tumor Sample | 6 doses |
Primary
Number of Participants With Grade 3 or Higher Adverse Events
Number of participants with grade 3 or higher adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.
Time frame: Up to 58 Months
Population: Analysis population for adverse events is Treated population.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Vaccine | Number of Participants With Grade 3 or Higher Adverse Events | Grade 3 | 1 Participants |
| Vaccine | Number of Participants With Grade 3 or Higher Adverse Events | Grade 4 | 0 Participants |
| Vaccine | Number of Participants With Grade 3 or Higher Adverse Events | Grade 5 | 0 Participants |
Secondary
Median Follow-up Time by Survival Status
Participants followed for survival status. Participants who were alive were noted as such as late as December 2020.
Time frame: Up to 14 Years
Population: Clinical outcomes assessed for the treated population.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Vaccine | Median Follow-up Time by Survival Status | Alive | 9.88 years |
| Vaccine | Median Follow-up Time by Survival Status | Dead | 6.24 years |